Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients

Aims: The purposes of this study were to investigate the influence of genetic polymorphisms of cytochrome P450 2C9 (CYP2C9)FNx013 and Vitamin K epoxide reductase complex subunit 1-1639 (VKORC1-1639) G >A and patient′s characteristics on warfarin dose requirement and to establish an equation for p...

Full description

Bibliographic Details
Main Authors: Burassakorn Subsuphan, Chatchai Chinpaisal, Manat Pongchaidecha, Wibun Phanthabordeekorn, Surawut Watana
Format: Article
Language:English
Published: Archives of Global Professionals 2016-01-01
Series:Archives of Pharmacy Practice
Subjects:
Online Access:http://www.archivepp.com/article.asp?issn=2045-080X;year=2016;volume=7;issue=1;spage=18;epage=25;aulast=Subsuphan
_version_ 1818364555448811520
author Burassakorn Subsuphan
Chatchai Chinpaisal
Manat Pongchaidecha
Wibun Phanthabordeekorn
Surawut Watana
author_facet Burassakorn Subsuphan
Chatchai Chinpaisal
Manat Pongchaidecha
Wibun Phanthabordeekorn
Surawut Watana
author_sort Burassakorn Subsuphan
collection DOAJ
description Aims: The purposes of this study were to investigate the influence of genetic polymorphisms of cytochrome P450 2C9 (CYP2C9)FNx013 and Vitamin K epoxide reductase complex subunit 1-1639 (VKORC1-1639) G >A and patient′s characteristics on warfarin dose requirement and to establish an equation for predicting the warfarin maintenance dose in Thai patients. Settings and Design: This is an observational, retrospective study in outpatients. Ninety-one outpatients receiving warfarin at Phaholpolpayuhasena Hospital, Kanchanaburi, were recruited to this study. Subjects and Methods: Whole blood, dose, and demographic data were collected. Blood samples were analyzed for the genetic polymorphism by restriction fragment length polymorphism technique. Statistical Analysis Used: Differences in baseline characteristics among genotypes were evaluated by analysis of variance or Kruskal-Wallis and the Mann-Whitney U-test or Chi-square test for parametric and nonparametric variables, respectively. Association between genetic factors and warfarin dose was based on Eta test, whereas associations between warfarin dose and polymorphisms were evaluated using Pearson correlation test. Stepwise regression was used to identify factors contributing to warfarin dose requirement followed by linear regression model to develop a warfarin dosing algorithm. Results: CYP2C9FNx011FNx011 (wild type) genotype was found in 90 patients (98.90%), and CYP2C9FNx011FNx013 was found in only 1 patient (1.10%). No CYP2C9FNx013FNx013 genotype was observed. Polymorphisms of VKORC1-1639 GG was found in 9 patients (9.89%) while GA and AA genotype were found in 30 patients (32.97%) and in 52 patients (57.14%), respectively. Patients with VKORC1-1639 AA genotype required statistically and significantly lower, average weekly warfarin dose (19.97 ± 7.61 mg) than GG genotype (37.89 ± 12.20 mg) and GA genotype (29.48 ± 11.50 mg) with the P < 0.05. Conclusions: Using stepwise multiple linear regression, VKORC1-1639 AA, age, and weight could explain about 45.3% of the variation of warfarin maintenance dose. Multivariate analysis of the equation indicated a significant negative correlation between warfarin dose and VKORC1-1639 AA and age, but a significant positive correlation between warfarin dose and weight. This suggested that VKORC1 genotyping may be more important in warfarin dose adjustment and should be a priority for genotype measurement.
first_indexed 2024-12-13T22:06:14Z
format Article
id doaj.art-6c688fdb7f764cdaadf739eba24e113c
institution Directory Open Access Journal
issn 2045-080X
language English
last_indexed 2024-12-13T22:06:14Z
publishDate 2016-01-01
publisher Archives of Global Professionals
record_format Article
series Archives of Pharmacy Practice
spelling doaj.art-6c688fdb7f764cdaadf739eba24e113c2022-12-21T23:29:49ZengArchives of Global ProfessionalsArchives of Pharmacy Practice2045-080X2016-01-0171182510.4103/2045-080X.174937Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patientsBurassakorn SubsuphanChatchai ChinpaisalManat PongchaidechaWibun PhanthabordeekornSurawut WatanaAims: The purposes of this study were to investigate the influence of genetic polymorphisms of cytochrome P450 2C9 (CYP2C9)FNx013 and Vitamin K epoxide reductase complex subunit 1-1639 (VKORC1-1639) G >A and patient′s characteristics on warfarin dose requirement and to establish an equation for predicting the warfarin maintenance dose in Thai patients. Settings and Design: This is an observational, retrospective study in outpatients. Ninety-one outpatients receiving warfarin at Phaholpolpayuhasena Hospital, Kanchanaburi, were recruited to this study. Subjects and Methods: Whole blood, dose, and demographic data were collected. Blood samples were analyzed for the genetic polymorphism by restriction fragment length polymorphism technique. Statistical Analysis Used: Differences in baseline characteristics among genotypes were evaluated by analysis of variance or Kruskal-Wallis and the Mann-Whitney U-test or Chi-square test for parametric and nonparametric variables, respectively. Association between genetic factors and warfarin dose was based on Eta test, whereas associations between warfarin dose and polymorphisms were evaluated using Pearson correlation test. Stepwise regression was used to identify factors contributing to warfarin dose requirement followed by linear regression model to develop a warfarin dosing algorithm. Results: CYP2C9FNx011FNx011 (wild type) genotype was found in 90 patients (98.90%), and CYP2C9FNx011FNx013 was found in only 1 patient (1.10%). No CYP2C9FNx013FNx013 genotype was observed. Polymorphisms of VKORC1-1639 GG was found in 9 patients (9.89%) while GA and AA genotype were found in 30 patients (32.97%) and in 52 patients (57.14%), respectively. Patients with VKORC1-1639 AA genotype required statistically and significantly lower, average weekly warfarin dose (19.97 ± 7.61 mg) than GG genotype (37.89 ± 12.20 mg) and GA genotype (29.48 ± 11.50 mg) with the P < 0.05. Conclusions: Using stepwise multiple linear regression, VKORC1-1639 AA, age, and weight could explain about 45.3% of the variation of warfarin maintenance dose. Multivariate analysis of the equation indicated a significant negative correlation between warfarin dose and VKORC1-1639 AA and age, but a significant positive correlation between warfarin dose and weight. This suggested that VKORC1 genotyping may be more important in warfarin dose adjustment and should be a priority for genotype measurement.http://www.archivepp.com/article.asp?issn=2045-080X;year=2016;volume=7;issue=1;spage=18;epage=25;aulast=SubsuphanCytochrome P450 2C9 isozymegenetic polymorphismVitamin K epoxide reductase complex subunit 1warfarin
spellingShingle Burassakorn Subsuphan
Chatchai Chinpaisal
Manat Pongchaidecha
Wibun Phanthabordeekorn
Surawut Watana
Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients
Archives of Pharmacy Practice
Cytochrome P450 2C9 isozyme
genetic polymorphism
Vitamin K epoxide reductase complex subunit 1
warfarin
title Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients
title_full Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients
title_fullStr Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients
title_full_unstemmed Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients
title_short Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients
title_sort warfarin dose requirement and cytochrome p450 2c9 and vitamin k epoxide reductase complex subunit 1 1639 genetic polymorphisms in thai patients
topic Cytochrome P450 2C9 isozyme
genetic polymorphism
Vitamin K epoxide reductase complex subunit 1
warfarin
url http://www.archivepp.com/article.asp?issn=2045-080X;year=2016;volume=7;issue=1;spage=18;epage=25;aulast=Subsuphan
work_keys_str_mv AT burassakornsubsuphan warfarindoserequirementandcytochromep4502c9andvitaminkepoxidereductasecomplexsubunit11639geneticpolymorphismsinthaipatients
AT chatchaichinpaisal warfarindoserequirementandcytochromep4502c9andvitaminkepoxidereductasecomplexsubunit11639geneticpolymorphismsinthaipatients
AT manatpongchaidecha warfarindoserequirementandcytochromep4502c9andvitaminkepoxidereductasecomplexsubunit11639geneticpolymorphismsinthaipatients
AT wibunphanthabordeekorn warfarindoserequirementandcytochromep4502c9andvitaminkepoxidereductasecomplexsubunit11639geneticpolymorphismsinthaipatients
AT surawutwatana warfarindoserequirementandcytochromep4502c9andvitaminkepoxidereductasecomplexsubunit11639geneticpolymorphismsinthaipatients